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Myeloproliferative syndromes (MPS) are a het-
erogeneous subclass of nonlymphoid hemato-
poietic neoplasms which are considered to be
intrinsic to hematopoietic cells. The causes of
MPS are largely unknown. Here, we demon-
strate thatmice deficient for retinoic acid recep-
torg (RARg), developMPS inducedsolely by the
RARg-deficient microenvironment. RARg/
mice had significantly increased granulocyte/
macrophage progenitors and granulocytes in
bone marrow (BM), peripheral blood, and
spleen. The MPS phenotype continued for the
lifespan of the mice and was more pronounced
in older mice. Unexpectedly, transplant studies
revealed this disease was not intrinsic to the
hematopoietic cells. BM from wild-type mice
transplanted into mice with an RARg/ micro-
environment rapidly developed the MPS, which
was partially caused by significantly elevated
TNFa in RARg/ mice. These data show that
loss of RARg results in a nonhematopoietic
cell-intrinsic MPS, revealing the capability of
the microenvironment to be the sole cause of
hematopoietic disorders.
INTRODUCTION
Studies of the roles of the hematopoietic microenviron-
ment have markedly increased in recent years, primarily
due to the identification of the bone-forming osteoblastCas being a critical component of the hematopoietic
stem cell (HSC) niche, the place where HSCs reside
and are primarily regulated (Calvi et al., 2003; Zhang
et al., 2003). In addition to this important role in regulat-
ing HSC self-renewal and differentiation, the bone
marrow (BM) microenvironment has been proposed to
consist of various other niches, first termed hematopoi-
etic inductive microenvironments (Trentin, 1971), which
are areas of the BM that are highly specialized for the
development of different maturing hematopoietic cell
types. This concept has been supported by the recent
identification of specific niches for B lymphocytes
(Tokoyoda et al., 2004) and megakaryocytes (Avecilla
et al., 2004) in the BM.
The hematopoietic microenvironment is not only sup-
portive for the development of hematopoietic cells but is
also known as a highly preferred site for the metastasis
of certain cancer cell types, including breast, prostate,
and melanoma cancers. A recent report demonstrated
that the cytokine receptor activator of NF-kB ligand
(RANKL), a member of the tumor necrosis factor (TNF)
family of cytokines, and which is expressed by osteo-
blasts, recruited epithelial and melanoma cancer cells
expressing RANK to the BM, where they subsequently
lodged and formed secondary tumors (Jones et al.,
2006). A similar chemoattractant role for nonhemato-
poietic cancer cells has been described for the chemo-
kine, CXCL12 (Muller et al., 2001), which is also expressed
by osteoblasts and is known to be an important mediator
of the homing of HSCs to the BM (Lapidot et al., 2005).
Despite these recent advances, however, virtually nothing
is known about the potential involvement of the BM
microenvironment in the initiation of different diseases of
hematopoietic origin, or the underlying factors that
influence the development of these disorders.ell 129, 1097–1110, June 15, 2007 ª2007 Elsevier Inc. 1097
Myeloproliferative syndromes (MPS) are a heteroge-
neous subclass of nonlymphoid hematopoietic neo-
plasms for which, with the exception of chronic myeloid
leukemia (CML), hypereosinophilic syndrome, and juve-
nile myelomonocytic leukemia, the causes remain largely
unknown (Van Etten and Shannon, 2004). To date, MPS
have been considered to be of hematopoietic origin
(Kogan et al., 2002), and the involvement of Bcr-Abl in
CML (Van Etten and Shannon, 2004) together with various
studies utilizing mouse models support this hypothesis
(Araki et al., 2004; Le et al., 2004; Passegue et al., 2004;
Wernig et al., 2006; Yan et al., 1994). Despite this, the
molecular basis of a significant subset of other MPS,
such as myelofibrosis and myelodysplastic syndrome
(MDS), remains unknown. Likewise, it is unclear as to
whether the hematopoietic (BM) microenvironment may
play an active part in promoting and/or supporting the
development of MPS.
Retinoic acid receptors (RARs) have been associated
with many different diseases, including cancer, and
retinoid-based therapies are increasingly being utilized
to treat such disorders (Altucci and Gronemeyer, 2001).
There are three RAR subtypes: RARa, RARb, and RARg,
all of which are highly conserved amongst species. The
vitamin A derivative, all-trans retinoic acid (ATRA), is the
naturally occurring ligand for all RARs.
The RARs are nuclear hormone receptors that act as
ligand-dependent transcriptional regulators; in their
liganded state, they activate transcription, whereas in
the nonliganded form, they repress transcription of their
target genes (Minucci and Pelicci, 1999). RARs have
numerous direct target genes which have retinoic acid
response elements in their promoter region (Balmer and
Blomhoff, 2002, 2005).
The generation of RAR-specific mutant mice has
allowed delineation of the different roles of the RARs in
organogenesis. We have recently shown that RARg, but
not RARa, null mice have 3-fold reduced numbers of
hematopoietic stem cells (HSCs) (Purton et al., 2006).
Here, we show that loss of RARg also results in a myelo-
proliferative-like disease. This MPS was not intrinsic to
the hematopoietic cell, but was induced by the RARg
null microenvironment. These novel findings reveal that
the microenvironment can play a dominant role in both
inducing and supporting the progression of hematopoietic
diseases such as MPS and potentially leukemias.
RESULTS
Loss of RARg Results in Perturbed Hematopoiesis
with Significantly Elevated Granulopoiesis
We have observed that RARa and RARg, but not RARb
isoforms are widely expressed in immature and maturing
hematopoietic cell types (Purton et al., 2006; and unpub-
lished data). Furthermore, the natural ligand for RARs,
ATRA, has potent effects on enhancing HSC self-renewal
and promoting differentiation of more mature granulocyte/
macrophage progenitors, which we have previously dem-1098 Cell 129, 1097–1110, June 15, 2007 ª2007 Elsevier Inc.onstrated are likely due to the different actions of RARa
and RARg on hematopoietic cells (Purton et al., 1999,
2000, 2006). RARa/ mice do not have any observable
hematopoietic defects in vivo (Kastner et al., 2001; Purton
et al., 2006), whereas RARg/ mice have significantly
reduced numbers of HSCs accompanied by increased
numbers of immature progenitor cells in their BM (Purton
et al., 2006). To determine if loss of RARg also affected
the production of mature hematopoietic cells, we exam-
ined the cellularity and hematopoietic composition of
peripheral blood (PB), BM, spleen, and thymus prepara-
tions obtained from RARg null, heterozygous, and wild-
type mice.
Eight-week-old RARg/ mice had significantly ele-
vated PB and BM leukocytes compared to their wild-
type littermates (Figure 1A). The elevated leukocyte levels
were comparable to those achieved by oncoretroviral
overexpression-induced models of MPD in C57Bl/6 back-
ground strains (Wernig et al., 2006). Spleen leukocyte
numbers were also elevated in RARg/ mice, but this
increase was not significant compared to the wild-type
mice. Eight-week-old RARg/ mice also presented with
splenomegaly, with spleen weights significantly increased
(1.5- to 3-fold) compared to their wild-type littermates. In
contrast, the thymic cellularity was significantly reduced
(25%) in RARg/ mice compared to their wild-type litter-
mates (Figure 1A). RARg/ mice have a growth defi-
ciency (Lohnes et al., 1993), and at 8 weeks of age were
approximately 20% smaller than their wild-type litter-
mates (Table S1 in the Supplemental Data available with
this article online). When normalized to body size, the
thymocyte cellularity was similar to that of wild-type
mice; however, there were significant increases in BM
and spleen cellularity in RARg/ mice.
We used immunophenotypical analysis to further
explore the effects of loss of RARg on the production of
mature hematopoietic cell lineages. There were marked
increases in the numbers of CD11b+ Gr-1+ granulocytes
in the PB (Figure 1B and Table S2), BM (Figure 1C and Ta-
ble S2), and spleen (Figure 1D and Table S2) of RARg/
mice compared to their wild-type littermates. These in-
creases occurred in both the immature and mature gran-
ulocyte compartments in the BM (Walkley et al., 2002)
(Figure 1C and Table S2).
There were also significant reductions in the numbers
of B lymphocyte subsets and erythrocytes in the BM of
the RARg/ mice (Tables S1 and S2); however, the num-
bers of these cells were unaltered in the PB and spleen
(Table S1). In contrast to RARg/ mice, RARg+/ mice
did not have altered numbers of mature hematopoietic
cells (Figure 1 and Table S1).
The Increased Granulocyte Compartment in RARg
Null Mice Arises at an Immature Progenitor Level
We further focused on investigating the mechanisms
behind the increased granulopoiesis in the RARg/
mice. Both the immature (CD11b+ Gr-1 dim) and mature
(CD11b+ Gr-1 bright) granulocyte subsets were
Figure 1. Eight-Week-Old RARg/ Mice
Have Elevated Numbers of Granulocytes
(A) Leukocyte cellularity in peripheral blood
(PB), bone marrow (BM), spleen, and thymus,
in addition to body weights of 8-week-old
RARg mutant mice.
(B–D) Flow cytometric analysis of granulocytes
and absolute numbers of granulocyte popula-
tions in 8-week-old RARg mutant mice:
(B) Representative PB granulocyte FACS
profiles, with the absolute numbers of granulo-
cytes (3 103 cells/ml blood) shown to the right of
each FACS profile.
(C) Representative BM granulocyte FACS
profiles, with the absolute numbers of imma-
ture granulocytes (Gr-1dim) and mature granu-
locytes (Gr-1bright; 3 106 cells/femur) shown
at the bottom of each FACS profile.
(D) Representative spleen granulocyte FACS
profiles, with the absolute numbers of granulo-
cytes (3 107 cells/spleen) shown to the right of
each FACS profile.
Data are expressed as the mean ±SEM (n = 6–9
per genotype). *p < 0.05; #p < 0.005 compared
to RARg+/+ mice (Student’s t test).significantly elevated in the BM, suggesting that the
increase in granulocytes was arising from an immature
progenitor population (Walkley et al., 2002). Furthermore,
we have recently shown that RARg/ mice have
increased numbers of immature colony-forming cells
(CFU-GEMM), which likely arise from accelerated differ-
entiation of HSCs into progenitor cells (Purton et al.,
2006). We therefore investigated the numbers of more
committed granulocyte progenitors in the BM of RARg/
mice.
The numbers of day 7 GM-CSF, SCF+G-CSF, and
G-CSF-responsive colony-forming cells (CFCs) were sig-
nificantly increased in RARg/ BM compared to that of
wild-type littermates (Figures 2A and 2B). The numbers
of more mature day 3 cluster-forming cells were also sig-
nificantly increased in these mutants compared to wild-
type mice (Figure 2C). The PB and spleen of RARg/
mice also had increased numbers of mature myeloid
CFCs (CFU-GM) (Figures 2C and 2D), but the numbers
of immature CFCs (CFU-GEMM) and immunophenotypic
HSC/progenitor cells in these organs were not signifi-Ccantly different to RARg+/+ mice (Table S3). These data
demonstrated that there were increased numbers of com-
mitted myeloid progenitors in the BM, spleen, and PB of
RARg/ mice. In contrast, the lack of CFU-GEMM and
HSC/progenitor cells in spleen and PB suggested that
RARg/ mice were not presenting with an HSC mobiliza-
tion phenotype.
To determine if the increased numbers of progenitors
could be due to altered cytokine sensitivity, we investi-
gated the numbers of BM CFCs formed in submaximal
and supramaximal concentrations of G-CSF (Walkley
et al., 2002). Both RARg/ and RARg+/+ BM cells showed
a similar cytokine response, hence it did not appear that
the progenitor cells had altered sensitivity to cytokines
(Figure 2F). A similar result was also observed in response
to IL-3 (unpublished data).
It was possible that the increased numbers of CFCs
were due to increased survival of these progenitors. To
assess this, we established CFC assays and delayed
cytokine addition to 24 and 48 hr. The numbers of CFCs
that formed were then assessed at 7 days postinitiation.ell 129, 1097–1110, June 15, 2007 ª2007 Elsevier Inc. 1099
Figure 2. Eight-Week-Old RARg/ Mice Have Increased Numbers of Granulocyte Progenitors
(A) Numbers of 7 day GM-CSF- or SCF+G-CSF-responsive colony-forming cells formed per 5 3 104 RARg+/+ or RARg/ BM cells.
(B) Numbers of 7 day G-CSF-responsive colony-forming cells formed per 5 3 104 RARg+/+ or RARg/ BM cells.
(C) Numbers of 3 day G-CSF-responsive cluster-forming cells (Cl-FCs) formed per 5 3 104 RARg+/+ or RARg/ BM cells.
(D) Numbers of 12 day CFU-GM formed per 1 3 105 RARg+/+ or RARg/ PB cells.
(E) Numbers of 12 day CFU-GM formed per 1 3 105 RARg+/+ or RARg/ spleen (Sp) cells.
(F) Numbers of 7 day G-CSF-responsive colony-forming cells generated per 5 3 104 RARg+/+ or RARg/ BM cells in response to submaximal and
supramaximal concentrations of G-CSF.
(G) Numbers of 7 day G-CSF-responsive colony-forming cells generated per 5 3 104 RARg+/+ or RARg/ BM cells in response to delayed addition
(24 hr or 48 hr) of G-CSF to the cultures.
(H) Frequencies of common myeloid progenitors (CMP), granulocyte macrophage progenitors (GMP), and megakaryocyte erythroid progenitors
(MEPs) present in RARg+/+ or RARg/ BM.
Results are expressed as mean ± SEM, n = 4 (A–C), n = 3 (D–H). *p < 0.05, #p < 0.005 compared to RARg+/+ (Student’s t test).There were no differences in the survival of progenitors
stimulated with G-CSF (Figure 2G), suggesting that the
myeloid expansion was not a secondary response due
to altered cell death of granulocyte progenitors.
Finally, we assessed the frequencies of common
myeloid progenitors (CMP), granulocyte/macrophage
progenitors (GMP), and megakaryocyte/erythroid progen-
itors (MEP) in RARg/ and RARg+/+ BM (Akashi et al.,
2000). The frequency of GMPs was significantly increased
(1.8-fold) in RARg/ BM compared to that of their wild-
type littermates (Figure 2H). Given that RARg/ mice
also had significantly increased BM leukocyte cellularity
compared to RARg+/+ mice (Figure 1A), this resulted in
an overall significant 2.1-fold increase in absolute num-
bers of GMPs in RARg null BM compared to wild-type BM.
RARg Null Granulocytes Have Normal
Functional Potential
The elevated granulopoiesis in RARg/ mice could be
compensatory if these cells had impaired functional
capacity, hence we tested several of their functional prop-
erties. The oxidative bursts response was similar in BM
samples of either genotype (Figure S1). Furthermore,
recruitment of cells after intradermal injection of Zymosan
A (which elicits an acute inflammation response) was
similar in RARg/ mice compared to their wild-type litter-1100 Cell 129, 1097–1110, June 15, 2007 ª2007 Elsevier Inc.mates (Figure S1), and there was no difference between
the morphology of the cell types that were recruited to
the ear in response to Zymosan A (data not shown).
Finally, there was no difference in the percentage of BM
granulocytes undergoing apoptosis when assessed by
annexin V staining (Figure S1). These data suggested
that RARg/ granulocytes had similar functional potential
to those of RARg wild-type granulocytes.
Aging RARg Null Mice Have a Profound
Myeloproliferative-Like Disease with Excessive
Extramedullary Hematopoiesis
We have recently reported that small numbers of RARg/
mice survive to approximately 12 months of age (Purton
et al., 2006). To determine if the increased granulocyte
phenotype persisted for the lifespan of RARg/ mice
we investigated the cellularity and hematopoietic compo-
sition of different organs obtained from 12-month-old
RARg/ and RARg+/+ mice.
The average PB leukocyte counts of the older RARg/
mice were dramatically increased compared to their wild-
type littermates (RARg+/+ = 10.54± 0.51; RARg/ = 29.6±
3.32 3 103/ml blood, p < 0.005). This was accompanied
by significantly increased numbers of granulocytes in the
PB, spleen and BM (Figures 3A–3C). Platelets were also
significantly elevated in the PB of these older knockout
Figure 3. Twelve-Month-Old RARg/
Mice Have Profoundly Elevated Numbers
of Mature and Immature Granulocytes
and Progenitor Cells
(A) Numbers of PB granulocytes in 12-month-
old RARg+/+ or RARg/ mice.
(B) Numbers of immature and mature granulo-
cytes in 12-month-old RARg+/+ or RARg/
BM.
(C) Numbers of granulocytes in 12-month-old
RARg+/+ or RARg/ spleen.
(D) Numbers of 12 day CFU-GEMM formed per
1 3 105 RARg+/+ or RARg/ PB cells.
(E) Numbers of 7 day GM-CSF- or SCF +
G-CSF-responsive colony-forming cells formed
per 53 104 RARg+/+ or RARg/ BM cells.
(F) Numbers of 12 day CFU-GEMM formed per
1 3 105 RARg+/+ or RARg/ spleen (Sp) cells.
(G) Numbers of 12 day CFU-GM formed per
1 3 105 RARg+/+ or RARg/ PB cells.
(H) Numbers of 7 day G-CSF-responsive
colony-forming cells generated per 5 3 104
RARg+/+ or RARg/ BM cells.
(I) Numbers of 12 day CFU-GM formed per
1 3 105 RARg+/+ or RARg/ spleen (Sp) cells.
(J) B lymphocyte and erythroid content in BM of
12-month-old RARg+/+ or RARg/ mice.
Results are expressed as mean ± SEM, n = 4–8
(A–C, J), n = 3 (D–I). *p < 0.05, #p < 0.005 com-
pared to RARg+/+ (Student’s t test).mice (RARg+/+ = 1480 ± 46.7; RARg/ = 1888 ± 66.7 3
103/ml blood, p < 0.005). In contrast, erythrocyte numbers
were significantly reduced in the PB of these aged mutant
mice (RARg+/+ = 9.77 ± 0.32; RARg/ = 8.87 ± 0.15 3
106/ml blood, p < 0.05).
Analysis of immature progenitors in these mice revealed
that RARg/ mice had significantly increased numbers
of CFU-GEMM and CFU-GM in their PB and spleen
(Figures 3D, 3F, 3G, and 3I), accompanied by strikingly
elevated numbers of lineage-restricted granulocyte/
macrophage CFCs in their bone marrow (Figures 3E and
3H). Significantly reduced numbers of mature B cells
and erythrocytes were also observed in the bone marrow
of the 12-month-old RARg/ mice (Figure 3J).
The frequencies of the lineage-negative, c-kit-positive,
Sca-1-negative (LKS) progenitor cells were significantly
increased in BM and spleens of 12-month-old RARg/
mice (Table S4). The HSC-containing lineage-negative,
c-kit-positive, Sca-1+ (LKS+) cells were also markedly
elevated in the spleens of these mice (Table S4).CHistological analysis of different organs of 9- to 12-
month-old mice revealed that the bone marrow of the
RARg/ mice was extremely hypercellular compared to
their wild-type littermates (Figures 4A and 4B). The trabec-
ular bones were virtually absent, and the cortical bones
were dramatically thinner in these older RARg/ mice
(Figure 4B). Bone marrow cells of the RARg/ mice
were predominantly developing myeloid cells, with some
megakaryocytes also obvious (Figures 4B and 4D).
Reduced B lymphocyte foci were also evident in the
spleens of the RARg/ mice compared to their wild-
type littermates (Figure S2). Myeloperoxidase staining
revealed that extramedullary hematopoiesis was occur-
ring in the liver of the RARg/ mice, however we did
not observe significant numbers of hematopoietic cells
in their kidneys compared to their wild-type littermates
(Figure S2). Strikingly, there were large foci of immature
and maturing hematopoietic cells (including granulocytes,
monocytes, megakaryocytes, and erythrocytes) develop-
ing in adipose tissue in these older of the RARg/ mice,ell 129, 1097–1110, June 15, 2007 ª2007 Elsevier Inc. 1101
Figure 4. Aging RARg/ Mice Exhibit
a Profound Myeloproliferative-Like
Disease
Representative sections of organs from 9–12-
month-old RARg+/+ or RARg/ mice.
(A and B) Hematoxylin and eosin stained sec-
tions of (A) RARg+/+ or (B) RARg/ BM. Origi-
nal magnification3 4. Identified are: trabecular
bone (large arrows), cortical bone (arrow-
heads).
(C and D) Hematoxylin and eosin stained
sections of (C) RARg+/+ or (D) RARg/ BM.
Original magnification 3 100. Identified are:
megakaryocytes (large arrows), granulocytes
(arrowheads).
(E and F) Hematoxylin and eosin stained sec-
tions of (E) RARg+/+ or (F) RARg/ adipose tis-
sue. Original magnification 3 20.
(G) Higher power magnification of a section of
RARg/ adipose tissue, stained with hema-
toxylin and eosin. Original magnification 3
100. Identified are: megakaryocytes (large
arrows), monocytes (double-headed arrows),
erythroid cells (short arrows), and granulocytes
(arrowheads).
(H) Myeloperoxidase (MPO) stained section
of RARg/ adipose tissue. Original magnifica-
tion 3 40. MPO-positive cells are brown.but not in their wild-type littermates (Figures 4E–4H). Dur-
ing their lifespan, however, none of the animals developed
leukemia or lymphoma.
Given the significantly increased myeloid compartment
in the mice with tissue infiltration, together with lack of
evidence of malignant transformation, the phenotype of
the RARg/ mice best corresponds with that of a myelo-
proliferative-like disease (MPD-like, or MPS) (Kogan et al.,
2002).
The Myeloproliferation in RARg Null Mice Is Not
Intrinsic to the Hematopoietic Compartment but
Is Induced by the RARg Null Microenvironment
Myeloproliferative-like diseases are thought to arise from
hematopoietic cells (Kogan et al., 2002). In a previous
study, we investigated the HSC frequency in the RARg/1102 Cell 129, 1097–1110, June 15, 2007 ª2007 Elsevier Inc.BM (Purton et al., 2006). During the 6 months of monitoring
recipient mice posttransplant, we did not observe a MPS in
wild-type mice that were transplanted with BM from the
RARg/ mice. However, these transplants were per-
formed with competing BM from wild-type congenic
mice, which may have masked or prevented the occur-
rence of the myeloproliferation. Therefore, we repeated
the transplants using whole BM without competing cells
and compared the hematopoietic phenotypes to that of
8-week-old RARg null mice (Figures 5A and 5B).
In contrast to the MPS observed in RARg/ animals,
at 8 weeks posttransplant all wild-type recipients of
either RARg+/+ or RARg/ BM had similar PB leukocyte
and granulocyte counts (Figures 5C and 5D). The PB
cellularity did not increase during the 6 months the
mice were monitored posttransplant (at 6 months
Figure 5. RARg/ Mice Have a Micro-
environment-Induced Myeloproliferative
Syndrome
(A and B) Peripheral blood (A) leukocyte and (B)
granulocyte counts in 8-week-old RARg+/+ and
RARg/ mice.
(C and D) Peripheral blood (C) leukocyte and (D)
granulocyte counts in CD45.1+ congenic recip-
ients transplanted with RARg+/+ or RARg/
BM, 8 weeks posttransplant.
(E and F) Peripheral blood (E) leukocyte and (F)
granulocyte counts in RARg+/+ or RARg/
recipients transplanted with CD45.1+ congenic
BM, 5 weeks posttransplant.
(G) B lymphocyte and erythroid content in BM
of RARg+/+ or RARg/ recipients transplanted
with RARg+/+ or RARg/ BM, 5–8 weeks post-
transplant.
Results are expressed as mean ± SEM, n = 6
(A, B, and G), n = 4–6 (C–F and G). *p < 0.05,
#p < 0.005 compared to RARg+/+ (Student’s
t test).posttransplant, leukocytes: RARg+/+ = 13.72 ± 0.93;
RARg/ = 11.5 ± 0.61 3 103/ml blood; granulocytes:
RARg+/+ = 0.91 ± 0.17; RARg/ = 0.80 ± 0.12 3 103/ml
blood). Bone marrow and spleen cellularity and lineage
contribution were also comparable between the recipi-
ents of the two genotypes (data not shown). Complete
reconstitution by RARg+/+ or RARg/ cells was con-
firmed by immunophenotypical analysis at each time
point of analysis, hence these results were not due to
an inability of the RARg/ BM cells to engraft in the
congenic recipients. These data therefore demonstrate
that the myeloproliferation did not occur when RARg/
hematopoietic cells were supported by a wild-type
microenvironment.
To determine if the microenvironment of the RARg null
mice was inducing the MPS we performed reciprocal
transplants. Congenic wild-type cells were transplanted
into lethally irradiated RARg+/+ or RARg/ recipientmice. By 5 weeks posttransplant, RARg/ mice trans-
planted with wild-type cells had significantly elevated PB
leukocytes and granulocytes (Figures 5E and 5F, Table
S5). The increases in leukocytes and granulocytes were
even more profound compared to 8-week-old nontrans-
planted RARg/ mice (Figures 5A and 5B, Table S2).
Immunophenotypical analysis confirmed the hematopoi-
etic cells were of wild-type origin rather than endogenous
recovery of RARg null hematopoietic cells.
In addition to the markedly elevated granulocytes in
these transplant recipients, BM B lymphopoiesis and
erythropoiesis were also significantly suppressed when
the wild-type congenic BM was transplanted into the
RARg/ mice (Figure 5G, Table S5). This was also more
profound compared to the B lymphocyte and erythrocyte
phenotype observed in the BM of 8-week-old RARg/
mutants (Tables S1 and S2). Hence, the myeloprolifera-
tive-like disease observed in RARg/ mice was notCell 129, 1097–1110, June 15, 2007 ª2007 Elsevier Inc. 1103
intrinsic to the hematopoietic cells, but was induced by the
RARg deficient microenvironment.
The RARg-Deficient Microenvironment Has Normal
HSC Niche Potential
We have previously reported that 8-week-old RARg/
mice have 3-fold reduced numbers of HSCs accompanied
by increased numbers of progenitors, including day 12
colony-forming unit-spleen (CFU-S) (Purton et al., 2006).
Given that the trabecular bone has been described as
being a key component of the HSC niche (Calvi et al.,
2003; Zhang et al., 2003) and that trabecular bone was vir-
tually absent in 12-month-old RARg/ mice (Figure 4B),
we wished to determine whether the microenvironment
of 8-week-old RARg/ mice was impaired in its ability
to support HSCs.
Histological sections of undecalcified tibiae revealed
significantly reduced trabecular bone in 8-week-old
RARg/ mice. Histomorphometric quantitation of the
tibiae sections from RARg/ mice demonstrated signifi-
cantly fewer and more dispersed trabeculae, decreased
trabecular volume but normal trabecular thickness in
tibiae obtained from RARg/ compared to wild-type
mice (L.E.P. and N.A. Sims, unpublished data). This
resulted in an overall 1.6-fold reduction in the number
of trabeculae in these mice. Despite this, there were
similar percentages of osteoblasts per bone surface in
8-week-old RARg/ mice compared to wild-type mice.
In contrast, the reduction in trabecular bone was accom-
panied by 1.6-fold increased numbers of osteoclasts per
bone surface, indicating increased osteoclastogenesis
was the predominant cause of the osteopenia in 8-week-
old RARg/ mice (L.E.P. and N.A. Sims, unpublished
data).
To assess whether this reduction in trabecular bone
impaired HSC self-renewal, we transplanted lethally irradi-
ated RARg+/+ or RARg/ recipient mice with wild-type
congenic BM. At 8 weeks posttransplant (a similar time
of exposure to the niche as that of the 8-week-old mutants
used in our previous studies [Purton et al., 2006]), we
assessed the numbers of CFCs, CFU-S, and HSCs (using
the limiting dilution assay) in the transplanted mice as
previously described (Purton et al., 2006; Szilvassy et al.,
1990; Walkley et al., 2005).
The numbers of CFU-GM were significantly increased
in PB and spleen, but not BM of RARg/ recipient
mice (Figures S3A–S3C). In contrast, there were no differ-
ences in the numbers of CFU-GEMM, LKS+, CFU-S, or
HSCs when wild-type BM was exposed to an RARg/
microenvironment compared to an RARg+/+ niche (Fig-
ures S3D–S3H). In vitro coculture assays revealed that
RARg/ stromal cells increased the production of matur-
ing wild-type BM cells during 14 days of culture
(Figure S3I). Collectively, these data suggest that the
RARg/ microenvironment increases the proliferation
and production of relatively mature hematopoietic cells
but does not affect the numbers of immature progenitors
and HSCs.1104 Cell 129, 1097–1110, June 15, 2007 ª2007 Elsevier Inc.Loss of RARg Results in Markedly Increased
Production of TNFa
In order to further elucidate the mechanisms behind the
myeloproliferation in the RARg/ mice, we examined
the expression of different inflammatory mediators, mye-
loid cytokines, and JunB, which is a putative target of
retinoic acid (Balmer and Blomhoff, 2002), and induces
an MPD (Passegue et al., 2004), in the hematopoietic
organs of the RARg mutants.
The expression of TNFa was significantly increased in
all three hematopoietic organs in RARg/ mice com-
pared to their wild-type littermates (Figure 6A). In contrast,
expression of other proinflammatory cytokines, IL-2 and
IL-6 were not markedly altered in the organs (Table S6).
The expression of IL-4 was significantly reduced in the
BM and slightly but significantly elevated in the spleen of
RARg/ mice (Table S6).
The expression of JunB was not altered in the BM (Table
S6). Neither of the two major myeloid cytokines, GM-CSF
or G-CSF, were elevated in any organ (Table S6). In con-
trast, G-CSF expression was significantly reduced in the
thymus of RARg/ mice compared to their wild-type
littermates (Table S6).
Given that we had not observed altered numbers of
T lymphocyte subsets in RARg/ mice (Table S1), we
further investigated the expression of TNFa in purified
populations of T lymphocytes. TNFa was predominantly
expressed by thymocytes expressing CD4 and/or CD8
(Table S6), consistent with a previous report investigating
the synthesis of TNFa by T lymphocyte populations (Giroir
et al., 1992).
TNFa is a proinflammatory cytokine that is known to
reduce the numbers of B lymphocytes in the BM and
preferentially promote granulopoiesis via reductions in
CXCL12 expression in BM (Ueda et al., 2004, 2005).
CXCL12 was unaltered in RARg/ BM and spleen, and
was elevated in the thymus (Table S6). Hence, the
reduced B lymphopoiesis observed in RARg/ BM (Table
S1) did not appear to be a result of reduced CXCL12
expression that normally occurs in the BM during
inflammation.
The Microenvironment-Induced Hematologic
Defects Are Partially Rescued When RARg
Null Mice Are Transplanted with TNFa Null
Hematopoietic Cells
To determine the contribution of deregulated TNFa signal-
ing to the occurrence of the MPS we transplanted RARg+/+
or RARg/ mice with TNFa/ BM. PCR genotyping of
BM obtained at the time of analysis confirmed full engraft-
ment of the transplanted mice with TNFa/ BM. Further-
more, Q-RT-PCR studies on BM, spleen and thymus
harvested from these mice confirmed that the levels of
expression of TNFa in RARg/ recipients were reduced
to that of the wild-type hosts transplanted with TNFa/
BM (data not shown).
Transplantation of TNFa/BM significantly reduced the
MPS in the RARg/ recipient mice (Figures 6 and S4).
Figure 6. The Microenvironment-Induced Myeloproliferative
Syndrome Observed in RARg/ Mice Is Partially Due to
Increased TNFa Signaling
(A) Relative expression of TNFa in cDNA from bone marrow, spleen,
and thymus extracts from 8-week-old RARg+/+ and RARg/ mice.
(B and C) Fold-differences observed in peripheral blood (A) leukocyte
and (B) granulocyte counts when TNFa+/+ or TNFa/ BM was trans-
planted into RARg+/+ compared to RARg/ recipient mice.
(D and E) Fold differences observed in BM (C) immature and (D) mature
granulocyte counts when TNFa+/+ or TNFa/ BM was transplanted
into RARg+/+ compared to RARg/ recipient mice.
(F and G) Fold-differences observed in spleen (E) leukocyte and (F)
granulocyte counts when TNFa+/+ or TNFa/ BM was transplanted
into RARg+/+ compared to RARg/ recipient mice.
(H) B lymphocyte and erythroid content in BM of RARg+/+ or RARg/
recipients transplanted with TNFa/ BM.
The levels of expression of TNFa were quantified by Q-RT-PCR and
are given as arbitrary units relative to b2-microglobulin. The data
represent the mean ± SEM of three different samples for eachWhen compared to the myeloproliferation observed in
RARg/ mice transplanted with wild-type BM, in
those transplanted with TNFa/ BM the fold increases
in PB leukocytes were reduced by approximately 50%
(Figure 6B). The numbers of BM leukocytes were not
altered (data not shown), whereas the spleen leukocyte
counts were restored to the levels of the wild-type
transplant recipients (Figure 6F).
While still elevated above that of wild-type recipients,
the fold-increases in granulocytes in all organs were
reduced by approximately 50% in BM and spleen, and
were 3-fold reduced in PB of RARg/ mice transplanted
with TNFa/ BM compared to those transplanted with
wild-type BM (Figures 6C, 6E, 6G, and S4).
The numbers of B220+/IgM+ cells remained significantly
lower in the BM of RARg/ recipients transplanted with
TNFa/ BM; however, the numbers of immature B220+/
IgM- cells in these recipients were restored to that of
wild-type recipients (Figure 6H). Finally, BM erythropoiesis
in RARg/ recipients transplanted with TNFa/ BM was
restored to the levels observed in wild-type recipients
(Figure 6H). These data indicate that deregulated TNFa
production significantly contributes to, but is not the sole
cause of, the myeloproliferative-like disease that is in-
duced by the microenvironment of RARg null mice.
Absolute Requirement of an RARg Null
Microenvironment to Sustain the Myeloproliferation
Approximately one-third of the RARg/ recipients had
PB leukocyte counts above 48 3 106 cells/ml (twice that
normally achieved by oncoretroviral MPD in a C57BL/6
background) at 8 weeks posttransplant and had to be
euthanized due to poor condition. These mice also had
severe anemia, reflected by significantly reduced PB
erythrocyte counts and hemoglobin content (data not
shown).
PB smears of these recipient mice revealed highly
elevated numbers of circulating immature myeloid cells
and numerous abnormal erythrocytes in the RARg/
recipients compared to the wild-type recipients (Figures
7A and 7B). FACS analysis confirmed the cells in both re-
cipient types were of wild-type donor origin (Figures 7C
and 7E), and showed that the majority (74.9 ± 1.89%,
n = 3) of the PB leukocytes in the RARg/ recipients
were immature myeloid cells coexpressing intermediate
levels of Gr-1 and CD11b (Figure 7F). In contrast, the
same donor cells transplanted into a wild-type microenvi-
ronment had PB content of approximately 15.1 ± 1.55%
cells (n = 4) expressing higher levels of Gr-1 and CD11b
(Figure 7D).
To determine if leukemic transformation of the cells had
occurred, we transplanted whole spleen cells consisting
genotype. #p < 0.005 compared to RARg+/+ (Student’s t test). Num-
bers in parentheses indicate fold-differences in expression between
RARg+/+ and RARg/ organs.
Transplant data are shown at 5-8 weeks posttransplant, n=4-6
recipients/group.Cell 129, 1097–1110, June 15, 2007 ª2007 Elsevier Inc. 1105
Figure 7. Absolute Requirement for an RARg/ Microenvironment to Sustain the Myeloproliferative-Like Disease
(A and B) Shown are representative May-Grunwald Giemsa-stained PB smears of (A) an RARg+/+ recipient and (B) an RARg/ recipient (with PB
leukocyte cellularity >48 3 106 cells/ml), both transplanted with the same donor CD45.1+ congenic wild-type bone marrow. Identified are: normal
granulocyte (large arrow), immature myeloid cells (arrowheads), and abnormal erythrocytes (double-headed arrows).
(C and D) FACS analysis of the RARg+/+ recipient shows high levels of donor cell reconstitution (C) and normal granulocyte profiles (D) in the PB.
(E and F) FACS analysis of the RARg/ recipient shows high levels of donor cell reconstitution (E) and abnormal granulocyte profiles (F) in the PB.
(G and H) Two representative FACS profiles of donor-derived PB granulocytes in secondary RARg+/+ recipients transplanted with 2.5 3 106 spleen
leukocytes obtained from the primary RARg/ recipient whose PB parameters are shown in (B), (E), and (F).
(I and J) Two representative FACS profiles of donor-derived PB granulocytes in secondary RARg/ recipients transplanted with 2.5 3 106 spleen
leukocytes obtained from the primary RARg/ recipient whose PB parameters are shown in (B), (E), and (F).
Data are shown at 8 weeks posttransplant, n = 3–5 recipients/group.of 2.5 3 106 leukocytes (containing 25% immature
granulocytes by FACS) from one such primary RARg/
recipient (Figures 7B, 7E, and 7F) into lethally irradiated
wild-type and RARg/ secondary recipient mice and
monitored their recovery during 8 weeks posttransplant.
At 8 weeks posttransplant, the average CD45.1+ donor
reconstitution was similar between groups (approximately
80%, data not shown). Surprisingly, the MPD-like pheno-
type was highly dependent upon the secondary recipient
genotype, demonstrating that the hematopoietic cells
had not undergone leukemic transformation during the1106 Cell 129, 1097–1110, June 15, 2007 ª2007 Elsevier Inc.primary transplant. When injected into wild-type second-
ary recipients, the percentage of donor-derived granulo-
cytes at 8 weeks posttransplant reverted to 26.6 ±
6.36% (n = 5), with many mature granulocytes evident
(Figures 7G and 7H). In marked contrast, when injected
into RARg/ recipients the splenic leukocytes reconsti-
tuted an average of 78.87 ± 9.31% immature granulocytes
in the PB of these recipients (Figures 7I and 7J, n = 5,
p < 0.003 wild-type versus RARg/ recipients). These
data therefore revealed that an RARg null microenviron-
ment was absolutely required to maintain the MPS.
DISCUSSION
Loss of RARg Results in a Myeloproliferative
Syndrome
Our studies show that loss of one of the major receptors
for vitamin A, RARg, results in a microenvironment-
induced MPS. The myeloproliferation likely arises from
the GMPs in the bone marrow and progresses markedly
with age. Profound loss of trabecular bone in 12-month-
old mice correlated with marked increases in the numbers
of immature CFCs detectable in PB and spleen and extra-
medullary myelopoiesis in other organs including liver and
adipose tissue. The microenvironment-induced myelo-
proliferation partially involves elevated TNFa expression,
as transplantation of TNFa/ BM into RARg/ mice
markedly ameliorated the MPD-like phenotype. However,
we did not observe any evidence of progression to leuke-
mia during the lifespan of these mice. Furthermore, the
RARg/ microenvironment was absolutely required to
sustain the MPS, as the phenotype reverted when either
BM (Figures 5C and 5D) or spleen cells (Figures 7G and
7H) from RARg/ mice were transplanted into wild-type
recipients.
An interesting observation in the older RARg/ mice
was the hematopoietic support potential of the adipose
tissue in these mice. Adipocytes are present in bone
marrow, albeit in low numbers in mice. Several previous
reports have suggested that adipocytes and adipose
tissue are capable of supporting hematopoiesis, including
myelopoiesis (Corre et al., 2004; Cousin et al., 2003;
Hangoc et al., 1993). Leptin, a hormone produced by
adipocytes, has been shown to augment myeloid colony
formation (Bennett et al., 1996). In addition, the leptin
receptor has been shown to be expressed by immature
myeloid cells (Gainsford et al., 1996). Adiponectin, another
protein expressed by adipocytes, has also been linked to
the regulation of immature myeloid cells, however, it has
been described as being a negative regulator of these
progenitors (Yokota et al., 2000). Interestingly, TNFa has
been shown to increase leptin and reduce adiponectin
expression in adipose tissue (Vettor et al., 2005), hence
it is possible that increased TNFa signaling directly
enhanced the hematopoietic support potential of adipose
tissue in the older RARg null mice. Regardless of the
mechanism, it appears that under conditions of extreme
hematopoietic stress, adipose tissue can serve as an
additional organ capable of supporting extramedullary
hematopoiesis.
A previous study also showed that vitamin A deficiency
(VAD) in mice resulted in myeloproliferation (Kuwata et al.,
2000). The VAD mice did not show external signs of infec-
tions, and sera screening and cytokine analysis of these
mice did not reveal any infectious cause of the myelopro-
liferation (Kuwata et al., 2000). This MPD-like phenotype
took approximately 14 weeks to become evident and
was more profound than that we have observed in non-
transplanted RARg/ mice (Figure 1) but less severe
than we have observed in approximately 1/3rd of RARg/recipients transplanted with wild-type congenic BM (Fig-
ures 6B, 6E, and 6F). When the VAD mice were fed a vita-
min A supplemented diet, their granulocyte phenotype
was reversed (Kuwata et al., 2000).
Although there are similarites in the studies performed
by Kuwata et al. (2000) to ours, there are also distinct
differences. The numbers of B220+ cells were unaltered
in the BM of VAD mice compared to those a fed vitamin
A-supplemented diet. In contrast, we observed a dramatic
reduction in the numbers of B lymphocytes in mice that
had an RARg null microenvironment. Furthermore, unlike
our findings, the numbers of colonies that formed from
BM from VAD mice were not significantly increased
compared to BM from mice fed the supplemented diet.
Instead, the increased granulocytes were found to result,
at least in part, to impaired apoptosis in the granulocytes
of VAD mice (Kuwata et al., 2000). We did not observe
altered granulocyte apoptosis in our studies (Figure S1).
A similar elevated granulocyte phenotype to the one ob-
served in RARg/ mice was also observed when mice
were fed a pan-RAR antagonist for 10 days (Walkley
et al., 2002). Like that of RARg/ mice, this increase
was accompanied by increased numbers of granulocyte
progenitors and was not due to altered survival properties
of granulocytes or their progenitors.
Vitamin A activates both the RARs and the retinoid X
receptors (RXRs), which form heterodimers with both
RARs and other members of the steroid hormone super
family to activate transcription. It is therefore likely that
some of the defects observed in VAD mice, including
impaired apoptosis of granulocytes were due to loss of
RXR function. Our studies show, however, that the
increased numbers of granulocytes observed in VAD
mice were likely due, at least in part, to loss of RARg func-
tion, and were not intrinsic to the hematopoietic cell.
TNFa is classically known as a proinflammatory
cytokine, which raises the possibility that the myeloprolif-
eration observed in RARg null mice results from an inflam-
matory process. However, the markedly elevated TNFa
expression we observed was not accompanied by
increases in other cytokines normally associated with
inflammation (IL-2, IL-6, or IL-4 [Table S6]), nor was the ex-
pression of IFNg deregulated (data not shown). Further-
more, there was no evidence of infection in RARg/
mice or in the VAD mice studied by Kuwata et al. (Kuwata
et al., 2000), and the myeloproliferation also occurred in
RARg/ mice that were administered antibiotics from
the time of weaning to analysis.
Emerging Evidence for Roles
of the Microenvironment in Inducing MPS
Myeloproliferative syndromes have, to date, been consid-
ered to be hematopoietic cell intrinsic. Studies utilizing
either transgenic mice such as JunB (Passegue et al.,
2004), Ptpn11 (Araki et al., 2004) or Nf1 (Le et al., 2004),
or oncoretroviral overexpression of acquired somatic
mutations such as Jak2V617F (Wernig et al., 2006) have
demonstrated that some MPS are intrinsic to theCell 129, 1097–1110, June 15, 2007 ª2007 Elsevier Inc. 1107
hematopoietic cell. However, given that the BM microen-
vironment is known to be an important regulator of hema-
topoiesis it is not unreasonable to speculate that the
microenvironment may play a larger role in the develop-
ment of MPS than previously thought. Our data and that
of Walkley et al. (2007 [in this issue of Cell]) support this
possibility.
Indeed, another recent study has provided additional
support to the potential role of the microenvironment in
regulating MDS. Conditional germline deletion of the
inhibitor of NF-kB (IkBa) resulted in hypergranulopoiesis
that was not cell autonomous (Rupec et al., 2005). Loss
of IkBa also resulted in increased numbers of dysplastic
hematopoietic cells (erythrocytes, megakaryocytes, and
granulocytes), resulting in MDS with progression to sec-
ondary acute myeloid leukemia (Rupec et al., 2005). The
mice died between 6 and 7 days after birth. Additional
studies in this report showed that Notch1 was upregulated
in IkBaD/D granulocytes, and the Notch1 ligand, Jagged1,
was shown to be upregulated in IkBaD/D hepatocytes
(Rupec et al., 2005). Inhibition of Jagged1 was able to
abolish the hypergranulopoiesis that occurred when
wild-type BM cells were cocultured with IkBaD/D hepato-
cytes (Rupec et al., 2005). It is unclear, however, whether
the nonhematopoietic microenvironment in the IkBaD/D
mice was the sole contributing factor to the myelodysplas-
tic syndrome and subsequent progression to leukemia
observed in IkBaD/D mice, or whether, like that demon-
strated in the accompanying paper by Walkley et al.
(2007), loss of IkBa was also required in hematopoietic
cells to exert these effects.
Retinoic acid receptors regulate many different gene
products and aberrant expression or function of RARs
have been identified in many different diseased states. It
is likely that there are multiple contributing factors to the
microenvironment-induced MPS observed in RARg/
mice. Increased production of TNFa is clearly involved,
as transplantation of TNFa/ BM into the RARg/
mice partially abrogated the myeloproliferative disease,
restored BM erythropoiesis to normal and reduced the se-
verity of the BM B lymphocyte defects observed in
RARg/ mice (Figures 6 and S4). There are numerous
links with aberrant expression of TNFa and human dis-
ease, including MDS (Flores-Figueroa et al., 2002) and
cancer (Szlosarek et al., 2006). Here, we provide the first
demonstration that an abnormal microenvironment
created by RARg deficiency can be the sole causative
mechanism for MPS. These data provide further support
for evaluating the bone marrow microenvironment as
a source of hematologic disease and potential target for
future therapies for such diseases.
EXPERIMENTAL PROCEDURES
Mice
RARg (Lohnes et al., 1993) mutant mice were backcrossed 10 gener-
ations onto the C57BL/6J background for these studies. For transplant
studies, donor mice were either B6.SJL-PtprcaPep3b/BoyJ (herein1108 Cell 129, 1097–1110, June 15, 2007 ª2007 Elsevier Inc.referred to as Ptprca; CD45.1+), obtained from Animal Resources
Centre, Perth, WA, Australia, or TNFa/ mice (Korner et al., 1997)
(generously provided by Dr Mark Smyth, Peter MacCallum Cancer
Centre, Melbourne, Vic., Australia). Recipient mice were either
CD45.1+ Ptprca mice or CD45.2+ RARg mutant mice. Except when
otherwise described, all mice were used between 8 and 10 weeks of
age. All experiments performed were approved by the Peter MacCal-
lum Cancer Centre animal experimentation ethics committee and were
conducted in strict compliance to the regulatory standards of the Aus-
tralian Code of Practice for the Care and Use of Animals for Scientific
Purposes.
Hematological Measurements and Phenotyping
Peripheral blood, BM, spleen, and thymic cell content were measured
on a Sysmex K1000 Auto analyzer (Sysmex).
Bone marrow, spleen, thymus, and hemolyzed PB cells were stained
with antibodies to B lymphocytes (B220-PE and IgM-FITC), T lympho-
cytes (CD4-FITC and CD8a-PE), granulocytes (CD11b-PE and Gr-1-
FITC), and erythrocytes (Ter119-PE) as previously described (Walkley
et al., 2002). Samples were analyzed on a FACSCAN (Becton
Dickinson).
Histopathological and Immunohistochemical Analysis
Whole mice were presented for necropsy fixed in Bouin’s fixative.
Tissues from all major organ systems were collected, processed,
sectioned, and stained with hematoxylin and eosin by routine
methods. Tissue sections with spleen, liver, kidney, adipose, and
BM were immunostained with myeloperoxidase (MPO; Abcam, Cam-
bridge, MA) to identify myeloid cells. Briefly, sections were deparaffi-
nized and dehydrated followed by antigen retrieval in Reveal Citra
buffer (Biocare Medical, Walnut Creek, CA) using a pressurized
antigen-decloaking chamber (Biocare). Sections were blocked with
normal serum followed by an avidin block then incubated overnight
at 4C with a rabbit polyclonal MPO (pre-diluted). The sections were
then blocked with biotin and incubated with biotinylated goat anti-
rabbit (1:200) for 35 min at room temperature. Lastly sections were
treated with streptavidin-peroxidase (Biogenix, San Ramon, CA),
Romulan AEC chromagen (as per manufacturer’s instructions), and
counterstained with Richard-Allan hematoxylin.
Transplant Studies
Recipient mice were lethally irradiated with a total dose of 10 Gy, given
in two equal fractions 3 hr apart, delivered by two opposing 137Cs
sources (Gammacell 40, Atomic Energy of Canada) on the day of trans-
plant. Each mouse was transplanted with 5 3 106 BM leukocytes
obtained from either RARg mutant (CD45.2+), Ptprca (CD45.1+) or
TNFa/ (CD45.2+) mice. The hematopoietic parameters of the trans-
planted mice were assessed between 5-8 weeks posttransplant.
Donor cell engraftment 5-8 weeks post-BMT was confirmed by either
FACS analysis after staining hemolyzed PB cells with CD45.1-PE and
CD45.2-FITC or by PCR-based assays on BM obtained from the trans-
planted mice (for TNFa/ donor BM cell transplants).
To assess potential leukemic transformation of the transplanted
cells, spleen cells consisting of 2.5 3 106 leukocytes obtained from
a RARg/ recipient were transplanted into new lethally irradiated
RARg/ or wild-type recipients. PB cellularity, donor cell engraftment
and hematopoietic cell content were analyzed 8 weeks post-BMT as
described above.
Quantitation of Progenitor Cell Content in RARg Mutant Mice
Colony-forming cell assays were performed using BM, spleen and
hemolzyed PB cells as previously described (Walkley et al., 2002). Pro-
genitor cell survival and cytokine responsiveness were measured as
previously described (Walkley et al., 2002). The numbers of common
myeloid progenitors (CMPs), granulocyte/macrophage progenitors
(GMPs) and megakaryocte/erythroid progenitors (MEPs) were
assessed as previously described (Walkley et al., 2005).
RNA extraction and Quantitative RT-PCR
Extraction of mRNA, synthesis of cDNA and Q-RT-PCR were per-
formed as previously described (Purton et al., 2006). All primers
used in these studies are given in Table S7.
Statistics
The results are expressed as the mean ± standard error of the mean
(SEM) for n given samples. Data were analyzed using the two-tailed
Student’s t test, with any p value less than or equal to 0.05 being
considered significant.
Supplemental Data
Supplemental Data include four figures and seven tables, and can be
found with this article online at http://www.cell.com/cgi/content/full/
129/6/1097/DC1/.
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